Mineralys Therapeutics (Nasdaq: MLYS) will report its financial results for the second quarter ended June 30, 2026, after market close on Tuesday, August 11, 2026. The company will host a conference call and live webcast at 4:30 p.m. ET for investors and analysts.
Loading...
Loading translation...
Positive
None.
Negative
None.
Market Context
Comparable earnings-date announcements produced 4.26% and 2.44% 24-hour reactions in the tag-specifi...
Analysis
Comparable earnings-date announcements produced 4.26% and 2.44% 24-hour reactions in the tag-specific history. For this scheduling notice, that record supplies context; Net Selling insider activity is a risk to monitor.
Scheduled fourth-quarter and full-year results with a 4:30 p.m. ET call
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Pattern Detected
Comparable earnings-date announcements were followed by positive 24-hour price reactions of 4.26% and 2.44%.
Key Terms
ckd, osa, aldosterone
3 terms
ckdmedical
"comorbid conditions such as chronic kidney disease (CKD)"
Chronic kidney disease (CKD) is a long-term condition where the kidneys gradually lose their ability to filter waste and fluids from the blood, like household filters that slowly clog and underperform over time. It matters to investors because CKD drives demand for drugs, medical devices, diagnostics and dialysis services, influences healthcare spending and reimbursement decisions, and creates regulatory or clinical-trial risks and market opportunities across the healthcare sector.
osamedical
"obstructive sleep apnea (OSA) and other diseases"
Obstructive sleep apnea (OSA) is a common sleep disorder where the upper airway repeatedly narrows or collapses during sleep, causing brief breathing stoppages that fragment rest and raise daytime tiredness and health risks. For investors, OSA creates sustained demand for diagnostic tests, therapy devices, drugs and monitoring services, so changes in clinical data, approvals, or reimbursement can materially affect revenue prospects for companies in the sleep-health sector.
aldosteronemedical
"dysregulated aldosterone"
Aldosterone is a hormone made by small glands above the kidneys that helps the body hold on to salt and water and release potassium, functioning like a household thermostat that adjusts fluid levels. It matters to investors because drugs or tests that change or measure aldosterone can alter treatment of high blood pressure, heart failure and kidney disease, affecting sales, trial outcomes and regulatory decisions in related healthcare markets.
RADNOR, Pa., Aug. 04, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and aldosterone-related adverse outcomes in comorbid conditions such as chronic kidney disease (CKD), obstructive sleep apnea (OSA) and other diseases driven by dysregulated aldosterone, announced it will report its financial results from the second quarter ended June 30, 2026, after the financial markets close on Tuesday, August 11, 2026.
A live webcast of the conference call may also be found on the “News & Events” page in the Investors section of the Mineralys Therapeutics website.
About Mineralys Therapeutics Mineralys Therapeutics is a biopharmaceutical company focused on developing medicines to target hypertension and related comorbidities such as chronic kidney disease, obstructive sleep apnea and other diseases driven by dysregulated aldosterone. Its initial product candidate, lorundrostat, is an investigational, proprietary, orally administered, highly selective aldosterone synthase inhibitor. Mineralys is based in Radnor, Pennsylvania, and was founded by Catalys Pacific. For more information, please visit https://mineralystx.com. Follow Mineralys on LinkedIn, Twitter and Bluesky.
When will Mineralys Therapeutics (MLYS) report its Q2 2026 financial results?
Mineralys Therapeutics will report its Q2 2026 financial results on Tuesday, August 11, 2026, after the U.S. financial markets close. According to Mineralys Therapeutics, the release will be followed by a conference call and webcast at 4:30 p.m. Eastern Time.
What time is the Mineralys Therapeutics (MLYS) Q2 2026 earnings conference call?
The Mineralys Therapeutics Q2 2026 earnings conference call is scheduled for 4:30 p.m. ET on August 11, 2026. According to Mineralys Therapeutics, this call will follow the financial results release after market close on the same day.
How can investors join the Mineralys Therapeutics (MLYS) Q2 2026 conference call by phone?
Investors can join by dialing 1-877-704-4453 domestically or 1-201-389-0920 internationally and using Conference ID 13760792. According to Mineralys Therapeutics, these numbers provide access to the August 11, 2026, 4:30 p.m. ET call.
Will there be a live webcast for the Mineralys Therapeutics (MLYS) Q2 2026 earnings call?
Yes, a live webcast will be available for the Q2 2026 earnings call. According to Mineralys Therapeutics, investors can access the webcast via the “News & Events” page in the Investors section of the company’s website on August 11, 2026.
Where can I find the webcast link for the Mineralys Therapeutics (MLYS) August 11, 2026 earnings call?
The webcast link for the August 11, 2026 earnings call will be on the Investors section’s “News & Events” page of the Mineralys Therapeutics website. According to Mineralys Therapeutics, the live webcast will coincide with the 4:30 p.m. ET conference call.
